Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
stavudine, lamivudine, efavirenz · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| stavudine extended-release, lamivudine, efavirenz | DRUG | - |
Inclusion Criteria: * Documented HIV infection * 18 years of age or older and weigh at least 40 kg * Two plasma HIV RNA levels below the limit of quantification (one at least 90 days prior to the screening visit and one within 30 days of the patients baseline visit) * Currently receiving a standard...
Top 20 of 28 competitors
Stavudine, lamivudine, and efavirenz are used for the treatment of HIV infections. This combination of small molecule antiretroviral drugs was studied as a once-daily regimen for HIV-1 infected subjects. The investigational combination was evaluated in a Phase 3 clinical trial.
Bristol-Myers Squibb Company (ticker: BMY) is the developer of the stavudine, lamivudine, and efavirenz combination. The company conducted a Phase 3 clinical trial of this antiretroviral regimen for HIV infections.
Stavudine, lamivudine, and efavirenz is in Phase 3 clinical development. The combination was studied in a completed Phase 3 trial for HIV infections. It remains investigational and has not been reported as approved.
Stavudine, lamivudine, and efavirenz was studied in one completed Phase 3 clinical trial, NCT00135369. The trial enrolled 300 participants with HIV infections in the United States and Puerto Rico. It evaluated switching from a twice-daily or more frequent HAART regimen to a once-daily regimen.
Stavudine, lamivudine, and efavirenz was studied as a once-daily regimen in the clinical trial NCT00135369. The trial evaluated switching HIV-1 infected subjects from a HAART regimen dosed twice daily or more frequently to this once-daily combination.